Unveiling the actual cost of Schizophrenia: An Activity-Based Costing (ABC) approach.

Publisher: Wiley Country of Publication: England NLM ID: 8605825 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1751 (Electronic) Linking ISSN: 07496753 NLM ISO Abbreviation: Int J Health Plann Manage

Original Publication: Chichester, Sussex, England : Wiley, c1985-

Mental Health Services* ; Schizophrenia*/drug therapy ; Schizophrenia*/epidemiology; Cost of Illness ; Health Care Costs ; Humans ; Prevalence

Background: Despite its relatively low lifetime prevalence, the health, social, and economic burden of Schizophrenia is very significant. In the last 10 years, several studies have analysed the economic burden of Schizophrenia, even if there is a lack of research that has considered the actual cost for the community as the result of each event in the patient's history.
Objective: The present study aims to cover this gap by proposing a novel model to evaluate better the cost of Schizophrenia with real data from medical records.
Methods: We applied (i) a 'real life' analysis of medical database to capture each event of the clinical history and healthcare that could have an economic impact; and (ii) a novel Activity-Based Costing model to quantify the overall annual economic burden of a patient with Schizophrenia treated by public mental health services. We carried out the study with 523 patients with a diagnosis of Schizophrenia in the Department of Mental Health of Bari, in the South of Italy.
Results: Our results reveal an overall cost of €41.290 per patient with Schizophrenia per year. Almost half of the cost is due to rehabilitation. The second most important factor is instead related to disability and loss of productivity.
Conclusions: We believe that the present approach represents the most effective method to properly estimate actual costs when real-life data are available compared with other studies mainly based on prevalence-based approaches.
(© 2021 John Wiley & Sons Ltd.)

American Psychiatric Association. Schizophrenia Spectrum and Other Psychotic Disorders. Diagnostic Stat Man Ment Disord. American Psychiatric Association; 2013.
NIMH » Schizophrenia [Internet]. [cited 2020 May 17]. https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml.
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005:0413-0433.
Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull [Internet]. 2008;34:173-180. 2007/06/19. Oxford University Press; https://pubmed.ncbi.nlm.nih.gov/17578893.
Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr BioMed Central. 2010;8:24.
Jin H, Mosweu I. The societal cost of Schizophrenia: a systematic review. Pharmacoeconomics. 2017;35:25-42. Springer International Publishing.
Marcellusi A, Fabiano G, Viti R, et al. Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. BMJ Open. 2018;8. BMJ Publishing Group.
Papa A, Mital M, Pisano P, Del Giudice M. E-health and wellbeing monitoring using smart healthcare devices: an empirical investigation. Technol Forecast Soc Change. 2020:153:119226. Elsevier Inc.
Orlando B, Ballestra LV, Magni D, Ciampi F. Open innovation and patenting activity in health care. J Intellect Cap. 2021;22:384-402. Emerald Group Holdings Ltd.
Scuotto V, Del Giudice M, Garcia-Perez A, Orlando B, Ciampi F. A spill over effect of entrepreneurial orientation on technological innovativeness: an outlook of universities and research based spin offs. J Technol Transf. 2020;45:1634-1654. Springer.
Chong HY, Teoh SL, Wu DBC, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357-373. Dove Medical Press Ltd.
Kovács G, Almási T, Millier A, et al. Direct healthcare cost of schizophrenia - European overview. Eur Psychiatry. 2018; 48:79-92. Elsevier Masson SAS.
Fasseeh A, Németh B, Molnár A, et al. A systematic review of the indirect costs of schizophrenia in Europe. Eur J Public Health [Internet]. 2018;28:1043-1049. Oxford University Press. https://pubmed.ncbi.nlm.nih.gov/30395217.
Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry. 2003;183:427-435.
Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. 1994;165:18-21. Royal College of Psychiatrists.
Teoh SL, Chong HY, Aziz SA, et al. The economic burden of schizophrenia in Malaysia. Neuropsychiatr Dis Treat. 2017;13:1979-1987. Dove Medical Press Ltd.
Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rössler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16:337-353. Blackwell Munksgaard.
Wimo A, Jönsson L, Dementia BW, 2010 undefined. Health economic aspects of dementia. books.google.com [Internet]. [cited 2020 May 17]. https://books.google.it/books?hl=en&lr=&id=j7A0DgAAQBAJ&oi=fnd&pg=PA371&dq=16)+Wimo+A.,+Jonsson+L,+Gustavsson+A.+Health+economic+aspects+of+dementia.&ots=AgH5Crk4zz&sig=z3oi0uMKrBpRwayv1A-sPYp1Xto.
Opoku-Boateng YN, Kretchy IA, Aryeetey GC, et al. Economic cost and quality of life of family caregivers of schizophrenic patients attending psychiatric hospitals in Ghana. BMC Health Serv Res. 2017;17:39-50. BioMed Central Ltd.
Behan C, Kennelly B, O’Callaghan E. The economic cost of schizophrenia in Ireland: a cost of illness study. Ir J Psychol Med [Internet]. 2008;25:80-87. College of Psychiatry of Ireland. [cited 2020 Sep 6] https://pubmed.ncbi.nlm.nih.gov/30282214/.
Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev [Internet]. 2012;2:1-8. Springer Verlag. [cited 2020 Sep 6]; https://pubmed.ncbi.nlm.nih.gov/22828440/.
Evensen S, Wisløff T, Lystad JU, Bull H, Ueland T, Falkum E. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull [Internet]. 2016;42:476-483. Oxford University Press. [cited 2020 Sep 6]; https://pubmed.ncbi.nlm.nih.gov/26433216/.
Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rössler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16:337-353.
McGuire T, Wells KB, Bruce ML, et al. Burden of illness. Ment Health Serv Res. 2002;4.
Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764-771. Physicians Postgraduate Press Inc.
Latorre V, Papazacharias A, Lorusso M, et al. Improving the “real life” management of schizophrenia spectrum disorders by LAI antipsychotics: a one-year mirror-image retrospective study in community mental health services. In: Lu K, ed. PLoS One [Internet]. Public Library of Science; 2020. [cited 2020 Sep 6];15:e0230051. https://dx.plos.org/10.1371/journal.pone.0230051.
Kaplan RS, William J, Bruns. Accounting and Management: Field Study Perspectives - Book - Harvard Business School [Internet]. Harvard Business School Press; 1987. [cited 2020 Sep 6]. https://www.hbs.edu/faculty/Pages/item.aspx?num=8849.
Drucker P. Management Challenges for the 21st Century (Google eBook) [Internet]. Harper Business; 2012. [cited 2020 Sep 6]. https://www.harpercollins.com/products/management-challenges-for-the-21st-century-peter-f-drucker?variant=32207433302050.
Claesson B, Edgren L. Activity-based costing in outpatient Psychiatry. Nord J Nurs Res [Internet]. 2001;21:42-45. SAGE Publications. [cited 2020 Sep 6]; http://journals.sagepub.com/doi/10.1177/010740830102100408.
Moreno K. Adaptation of activity-based-costing (ABC) to calculate unit costs in Mental Health Care in Spain. Eur J Psychiatry. 2007;21:117-123. University of Zaragoza.
van Rensburg ABRJ, Jassat W. Acute mental health care according to recent mental health legislation Part II. Activity-based costing. Afr J Psychiatry (South Africa). 2011;14:23-29.
El Alaoui S, Lindefors N. Combining time-driven activity-based costing with clinical outcome in cost-effectiveness analysis to measure value in treatment of depression. PLoS One [Internet]. 2016;11. Public Library of Science. [cited 2020 Sep 6]; https://pubmed.ncbi.nlm.nih.gov/27798655/.
Italian Health Care Ministry. Rapporto sulla salute mentale [Internet]. [cited 2020 Sep 6]. http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=5014&area=salutementale&menu=vuoto.
Buchanan JM, Stubblebine WC. Externality. Economica. 1962;29.
Jacobsson F, Carstensen J, Borgquist L. Caring externalities in health economic evaluation: how are they related to severity of illness? Health Policy (New York). Elsevier. 2005;73:172-182.
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry [Internet]. 2021;8:387-404. Elsevier Ltd. [cited 2021 Jul 6]; https://pubmed.ncbi.nlm.nih.gov/33862018/.
Adelle C, Weiland S. Policy assessment: the state of the art. Impact Assess Proj Apprais. 2012;30.
Impact Assessment Toolkit version 2.0. http//www.bis.gov.uk/ia-toolkit2001.
Nove A, Cometto G, Campbell J. Assessing the health workforce implications of health policy and programming: how a review of grey literature informed the development of a new impact assessment tool. Hum Resour Health. 2017;15:1-10.
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimer’s Dement. 2013;9:1-11.

Otsuka Pharmaceutical Italy Srl

Keywords: activity-based costing; cost of Schizophrenia; public mental health services

Date Created: 20211223 Date Completed: 20220517 Latest Revision: 20220517

20240105

10.1002/hpm.3405

34939215